Cargando…
Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity
BACKGROUND: Retinoic acid (RA) controls diverse physiological functions including weight regulation and energy metabolism. It has been reported that mice lacking ALDH1A1, one of the aldehyde dehydrogenases (ALDH) that synthesize RA, are healthy and resistant to weight gain, raising the possibility t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238815/ https://www.ncbi.nlm.nih.gov/pubmed/33934107 http://dx.doi.org/10.1038/s41366-021-00818-1 |
_version_ | 1783714970946502656 |
---|---|
author | Haenisch, Michael Ngyuen, Tai Fihn, Conrad A. Goldstein, Alex S. Amory, John K. Treuting, Piper Brabb, Thea Paik, Jisun |
author_facet | Haenisch, Michael Ngyuen, Tai Fihn, Conrad A. Goldstein, Alex S. Amory, John K. Treuting, Piper Brabb, Thea Paik, Jisun |
author_sort | Haenisch, Michael |
collection | PubMed |
description | BACKGROUND: Retinoic acid (RA) controls diverse physiological functions including weight regulation and energy metabolism. It has been reported that mice lacking ALDH1A1, one of the aldehyde dehydrogenases (ALDH) that synthesize RA, are healthy and resistant to weight gain, raising the possibility that inhibiting this enzyme might treat obesity. We previously demonstrated that treatment with a pan-ALDH1A enzyme inhibitor, WIN18446, suppressed weight gain in mice fed a high fat diet (HFD), but caused increased hepatic lipidosis and reversible male infertility. METHODS: A series of piperazine compounds that inhibited ALDH1A1 were identified and their inhibitory activity was characterized in vitro using purified recombinant enzymes and cell-based assay systems. One potent compound, FSI-TN42 (N42) was examined for its oral bioavailability and pharmacodynamic effects. In addition, its effect on weight gain was investigated by daily oral administration to C57BL/6 male mice receiving a HFD, and compared with mice receiving WIN18446 or vehicle alone (n=6/group, 200 mg compound/kg body weight) for 5 weeks. Body weights were measured weekly, and a glucose tolerance test was performed after 4 weeks of treatment. Tissues were collected to determine changes in adipose weight, hepatic lipidosis, retinoid metabolism, and expression of genes associated with RA and lipid metabolism. RESULTS: N42 irreversibly binds and inhibits ALDH1A1 in vitro with a low nM IC(50) and 800-fold specificity for ALDH1A1 compared to ALDH1A2. Daily oral administration of N42 significantly suppressed weight gain (P<0.05) and reduced visceral adiposity (p<0.05) in mice fed a HFD without the hepatic lipidosis observed with WIN18446 treatment. CONCLUSIONS: We developed a potent and specific inhibitor of ALDH1A1 that suppressed weight gain in mice fed a HFD. These findings demonstrate that inhibition of ALDH1A1 is a feasible target for drug development to treat and/or prevent obesity. |
format | Online Article Text |
id | pubmed-8238815 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-82388152021-11-01 Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity Haenisch, Michael Ngyuen, Tai Fihn, Conrad A. Goldstein, Alex S. Amory, John K. Treuting, Piper Brabb, Thea Paik, Jisun Int J Obes (Lond) Article BACKGROUND: Retinoic acid (RA) controls diverse physiological functions including weight regulation and energy metabolism. It has been reported that mice lacking ALDH1A1, one of the aldehyde dehydrogenases (ALDH) that synthesize RA, are healthy and resistant to weight gain, raising the possibility that inhibiting this enzyme might treat obesity. We previously demonstrated that treatment with a pan-ALDH1A enzyme inhibitor, WIN18446, suppressed weight gain in mice fed a high fat diet (HFD), but caused increased hepatic lipidosis and reversible male infertility. METHODS: A series of piperazine compounds that inhibited ALDH1A1 were identified and their inhibitory activity was characterized in vitro using purified recombinant enzymes and cell-based assay systems. One potent compound, FSI-TN42 (N42) was examined for its oral bioavailability and pharmacodynamic effects. In addition, its effect on weight gain was investigated by daily oral administration to C57BL/6 male mice receiving a HFD, and compared with mice receiving WIN18446 or vehicle alone (n=6/group, 200 mg compound/kg body weight) for 5 weeks. Body weights were measured weekly, and a glucose tolerance test was performed after 4 weeks of treatment. Tissues were collected to determine changes in adipose weight, hepatic lipidosis, retinoid metabolism, and expression of genes associated with RA and lipid metabolism. RESULTS: N42 irreversibly binds and inhibits ALDH1A1 in vitro with a low nM IC(50) and 800-fold specificity for ALDH1A1 compared to ALDH1A2. Daily oral administration of N42 significantly suppressed weight gain (P<0.05) and reduced visceral adiposity (p<0.05) in mice fed a HFD without the hepatic lipidosis observed with WIN18446 treatment. CONCLUSIONS: We developed a potent and specific inhibitor of ALDH1A1 that suppressed weight gain in mice fed a HFD. These findings demonstrate that inhibition of ALDH1A1 is a feasible target for drug development to treat and/or prevent obesity. 2021-05-01 2021-07 /pmc/articles/PMC8238815/ /pubmed/33934107 http://dx.doi.org/10.1038/s41366-021-00818-1 Text en http://www.nature.com/authors/editorial_policies/license.html#termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Haenisch, Michael Ngyuen, Tai Fihn, Conrad A. Goldstein, Alex S. Amory, John K. Treuting, Piper Brabb, Thea Paik, Jisun Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity |
title | Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity |
title_full | Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity |
title_fullStr | Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity |
title_full_unstemmed | Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity |
title_short | Investigation of an ALDH1A1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity |
title_sort | investigation of an aldh1a1-specific inhibitor for suppression of weight gain in a diet induced mouse model of obesity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238815/ https://www.ncbi.nlm.nih.gov/pubmed/33934107 http://dx.doi.org/10.1038/s41366-021-00818-1 |
work_keys_str_mv | AT haenischmichael investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity AT ngyuentai investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity AT fihnconrada investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity AT goldsteinalexs investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity AT amoryjohnk investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity AT treutingpiper investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity AT brabbthea investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity AT paikjisun investigationofanaldh1a1specificinhibitorforsuppressionofweightgaininadietinducedmousemodelofobesity |